FLT3 and hematologic disorder: Another phase 1 clinical trial (NCT06325748) is currently enrolling adult patients with R/R CD33 and/or FLT3 expressing heme malignancies for allogenic treatment using SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy candidate that selectively targets hematologic malignancies, using three technologies: 1) the OR GATE, which is an activating CAR that targets either or both CD33 and FLT3, 2) the NOT GATE, which recognize and protect healthy cells from being killed.